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The American Society of Breast Surgeons (ASBrS)
encourages an evidence-based and patient value focused
approach to contralateral prophylactic mastectomy (CPM).
The ASBrS convened a panel of experts to develop a
consensus statement on CPM.1 The majority of women will
obtain no oncologic benefit from CPM, and therefore CPM
should be discouraged in average-risk women with uni-
lateral breast cancer. Consideration of the patient’s
preferences and values and an informed discussion of the
risks and benefits of CPM is recommended for all patients
pursuing mastectomy, along with a direct recommendation
by the surgeon for or against CPM.
SENTINEL LYMPH NODE SURGERY FOR CPM
The benefit of performing sentinel lymph node (SLN)
surgery at the time of CPM is that the lymph nodes have been
evaluated in the event that an occult malignancy is found, but
the downside is increased surgical morbidity such as lym-
phedema. By meta-analysis, the risk of lymphedema after
SLN alone is 5.6 % (95 % CI 6.1–7.9 %) and increases with
longer follow-up.2 The chance of finding occult invasive
disease in a prophylactic mastectomy is 1.8 %.3,4 An addi-
tional small percent of CPM specimens harbor noninvasive
disease that would not require nodal evaluation. The rate of
nodal positivity in patients with occult malignancy in CPM is
only 1.3 %.3,5,6 Considering these data, routine SLN surgery
at time of CPM places more patients at risk of lymphedema
than would be expected from the 1–2 % of patients with occult
disease undergoing axillary dissection.7 Therefore the con-
sensus group does not recommend routine SLN for CPM.
Patients at higher risk of contralateral occult malignancy
are postmenopausal patients, those with triple-negative,
locally advanced, inflammatory, or invasive lobular dis-
ease.3,8–10 MRI at the time of breast cancer diagnosis
identifies occult contralateral disease 2–4 % of the time.11
Suspicious lesions in the contralateral breast should be
biopsied, but if a biopsy is not done, SLN surgery should
be considered for highly suspicious lesions.
Summary Sentinel lymph node surgery on the CPM side
should not be routinely performed.
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COST OF CPM VERSUS SURVEILLANCE
There is robust literature to support the use of CPM as a
cost-effective strategy in patients with hereditary breast
cancer syndromes.12–16 Anderson et al. demonstrated that
the most cost-effective strategy, with and without quality
adjustment, for women with BRCA1 or BRCA2 mutations
was prophylactic bilateral salpingo-oophorectomy with
bilateral mastectomy.12
Simulation models analyzing costs for CPM versus
surveillance in patients with sporadic breast cancer reveal
disparate findings.17,18 An initial Markov model study
found that CPM was cost effective compared with
surveillance for patients younger than 70 years, but this
finding was highly dependent on the quality of life
assumptions.17 A second study that included operative
complications and breast reconstruction costs used a deci-
sion-tree model and concluded that although CPM resulted
in a cost savings over surveillance for women younger than
50 years, it also reduced quality of life years.18 When MRI
was inserted in the model as the primary method of
screening, the cost-effectiveness of CPM increased. Loss of
quality of life years was largely attributed to complications
from reconstructive procedures. The two models differ in
the assumptions regarding quality of life. If we assume an
improvement in quality of life after CPM, then CPM could
be cost effective. Alternatively, if quality of life is
decreased, CPM would not be a cost-effective strategy. The
available data on cost effectiveness for CPM is limited to
modeling studies and therefore does not provide strong
scientific evidence to support CPM as a cost effective
strategy.
Summary CPM is a cost-effective strategy for women
with BRCA mutations. At this time, there is insufficient
evidence to support the concept of superior cost effec-
tiveness for CPM in women with sporadic breast cancer
and the cost effectiveness is highly dependent on the
quality of life assumptions.
IMPACT OF CPM ON PSYCHOSOCIAL
OUTCOMES
The decision to undergo CPM is intensely personal and
frequently driven by a shifting balance between perceived
future breast cancer risk, anxiety over annual screening and
potential future diagnostic procedures, and the unknown
physical, emotional, and cosmetic outcomes of the surgery.
Long-term outcomes for women who have undergone
CPM report that 86–90 % of respondents were satisfied
with the decision to undergo prophylactic surgery.19–21
With 20 years of follow-up more than 90 % of women
definitely or probably would choose to undergo CPM
again.22 However, many of these same women report dis-
satisfaction with areas such as body image, chronic pain,
problems with implants, and sexual changes even though
they noted overall satisfaction with their decision mak-
ing.23 In a study of 296 women who participated in the
National Prophylactic Mastectomy Registry and provided
detailed responses to a survey evaluating their outcomes
with CPM, only 6 % expressed regrets with the decision;
but of these women 39 % reported poor cosmetic outcomes
and 22 % reported a reduced sense of sexuality.24 Studies
with longer follow-up had outcome data only on a pro-
portion of the initial cohort, introducing possible bias
between responders and nonresponders, limiting the
strength of the evidence.
Few studies have examined quality of life between CPM
and non-CPM patients. One study, approximately 10 years
ago, showed no difference in quality of life between
patients undergoing CPM and those undergoing unilateral
mastectomy or lumpectomy.21 In a study from Sweden, no
differences in overall health-related quality of life were
identified up to two years post surgery in 60 women
undergoing (delayed) CPM.25
Summary While 80–90 % of women report satisfaction
with their decision to undergo CPM, 20–30 % of these
women report postsurgical dissatisfaction with cosmesis,
body image, and sexuality. Studies show that CPM does
not affect overall quality of life parameters. Women should
be counseled on the potential long-term outcomes of CPM
on body image and sexuality.
SHOULD PERFORMANCE OF CPM BE A
QUALITY MEASURE?
Quality measures are used to compare the performance
of individual surgeons or institutions and can be viewed as
‘‘external’’ or ‘‘internal’’. External quality measures can
support pay-for-performance programs or be used for
public reporting and are designed to help patients and
purchasers make healthcare choices among providers,
while internal measures are primarily used to identify
quality-improvement initiatives within a given healthcare
system or hospital. In evaluating the use of CPM as a
quality measure, the most important consideration is how it
would impact behavior of the surgeon, hospitals, pur-
chasers, and payors and ultimately patient care. If CPM is a
publicly reported measure, one could argue that patients
could self-select for surgeons who align with their prefer-
ences based on reported CPM rates, but it could also
pressure surgeons to decline to perform this procedure.
CPM should not be used as a high-stakes quality measure
such as for public reporting or selective referral because of
a lack of a clearly defined outcome that is improved for all
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patients, ambiguity around exclusion criteria for the
denominator, and significant potential for unintended
consequences that can limit access to appropriate care.
The best potential for CPM is as an internal measure to
inform performance review and quality-improvement
efforts. Quality measures that are used for internal report-
ing do not require the same level of rigor and validity as
those used for higher-stakes measurement. Such quality
measures can be critical in determining the etiology of
overutilization, particularly for a procedure such as CPM
where there is wide variation in observed rates by surgeon
and hospital that may represent provider bias rather than
patient preference.
In summary, the use of CPM as a quality measure is
limited because of a lack of a clear association with an
improved outcome and its potential for unintentionally
decreasing access to patients who may be at high risk for
contralateral cancer. Internal measurement to inform a
better understanding of the role physician and institutional
bias and practice patterns could play in driving the
observed increased utilization of CPM is the only potential
application at this time. The ultimate goal of CPM as an
internal quality measure is to minimize unnecessary, risky
surgery and to track the effectiveness of new shared deci-
sion models as they become available.
Summary CPM should not be used as a national quality
measure.
PERSPECTIVES ABOUT CONTRALATERAL
PROPHYLACTIC MASTECTOMY FROM OTHER
COUNTRIES: THE UNITED KINGDOM AND
MAINLAND EUROPE
The United Kingdom has significantly lower rates of
CPM than the United States, although recently rates of
CPM have increased in the United Kingdom with one study
showing an increase from 2.0 to 3.1 %.26 In Switzerland,
studies have not shown any increased trend for CPM.27
Senior surgeons on the European Breast Cancer Board
(UEMS) do not feel CPM is increasing in Scandinavia,
Spain, Austria, or central Europe (personal communica-
tion). CPM drivers in the United Kingdom are similar to
the United States, including influence of the media, poor
understanding of the risks of relapse and the limited impact
of CPM on these risks, poor understanding of contralateral
breast cancer risk and risks associated with breast recon-
struction, and fear of recurrence. In addition, increased
access to breast reconstruction, desire for symmetry, and
worry about missing future cancers from mammogram
screening also motivate patients to pursue CPM.28 A
multidisciplinary approach to managing requests for CPM
has been shown to reduce CPM rates.29
One key difference between the United Kingdom and
the United States is that most private health insurers and
some National Health Service commissioners in the United
Kingdom will not fund CPM unless the patient is a BRCA
carrier. Another key difference between the two countries
is that breast surgeons in the United Kingdom learn to
perform oncoplastic procedures as part of their formal
training and therefore more commonly perform oncoplastic
breast conservation to maintain symmetry.
UK/European Guidelines
• UK Breast Cancer clinical reference group (2016)
states ‘‘There is no evidence of a survival benefit for
contralateral risk-reducing mastectomy—this should
not be offered, except for women with BRCA muta-
tions, and should only be performed after a full
discussion of the risks and benefits and with appropriate
psychological support.’’
• The National Institution for Health and Care Excellence
(NICE) has no recommendations about CPM, but
guidelines are due for review 2016/2017.
• EUSOMA (the European Society of Breast Cancer Spe-
cialists) and EUROPA DONNA (the European Breast
Cancer Coalition) do not have any published guidelines.
Summary CPM rates are rising in the United Kingdom but
not mainland Europe. CPM drivers are similar between the
United Kingdom and the United States. Payment for CPM is
not as freely available in Europe as in the United States.
PATIENT PERSPECTIVES ON CPM
In numerous studies, many patients arrived at a decision
to have a CPM based on two main themes—a decision
based in fear or a decision to ‘‘take control.’’ Patient’s fear
translated into an ‘‘overestimated risk of recurrence, con-
tralateral breast cancer, and death.’’30 Breast cancer
surgical treatment decisions are made when a patient’s best
decision-making skills are severely impaired by the stress
and anxiety of their cancer diagnosis.31
The increased media focus on surgical treatment options
exploded after Angelina Jolie, a prominent celebrity and
actress, announced her decision to undergo bilateral pro-
phylactic mastectomy after finding out she was a BRCA1
gene mutation carrier. This increased media exposure for a
woman choosing bilateral mastectomy raised the visibility
of prophylactic surgical options and generated considerable
confusion for other newly diagnosed patients as to whether
a CPM was indicated for them. This confusion has surfaced
in decision-making conversations with patients and sur-
geons when discussing surgical options.32
Ultimately, fear of cancer recurrence and input from
family and friends influence decisions to undergo
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CPM.33,34 Although fear of recurrence is a major concern
among breast cancer survivors after surgery, no standard
strategies exist that qualify or alleviate this distress.35
Patients can regret irrevocable surgical decisions made
without carefully considering all available options.36
Summary The ‘‘Jolie Effect’’ coupled with fear-based
decision making impact patient’s consideration of CPM.
Additional educational resources on risks and benefits,
stronger patient engagement, and enhanced decision-mak-
ing guidelines are needed.
SHARED DECISION MAKING FOR CPM
Most women who have undergone CPM report having
taken an active role in the decision process, with roughly
45–57 % reporting making the decision mainly on their
own, and only 15–38 % reporting sharing in the decision
process.20,37 Although the majority of patients who con-
template CPM identify their physicians as a key source of
information, in a cohort of young women (younger than
40 years), few rate a desire to follow physician recom-
mendation as very important in their decision making.38
Critical factors that were highly important to patients in the
CPM decision-making process included: reducing their
chance of a CBC (98 %), achieving peace of mind (95 %),
improving survival/extending life (94 %), feeling at
increased risk for CBC (87 %), and preventing metastatic
spread (85 %).38
Many patients consider CPM prior to seeing their sur-
geon. In a recent study, more than 50 % of women with
sporadic breast cancer were initially interested in CPM, but
only 10 % underwent CPM.39 Although patients claim
CPM discussion rates of 45–80 % with their doctor, only
half of patients relay that their doctors outlined reasons not
to have CPM.38,39 Given that approximately one-third of
patients in one study experienced worse than expected
results, this discussion may serve as an educational
opportunity for providers to optimize informed consent.20
An accurate model that provides realistic numbers
regarding CBC risk and impact of CPM and incorporates
patient desires and other psychosocial factors may serve to
enhance shared decision making between the patient and
provider.
Summary Shared decision making that includes a com-
prehensive discussion of risks and benefits of CPM is
important.
COUNSELING PATIENTS ON CONTRALATERAL
PROPHYLACTIC MASTECTOMY
Surgeons should strive to help patients make decisions
that are informed and evidence based. They should
encourage patients to make decisions that are concordant
with their personal values. They should inform patients
about the low risk of CBC for most patients, how CPM
impacts survival and recurrence, complications and risks of
CPM, and how CPM can impact body image and cosmesis.
Asking patients about the importance of keeping the breast,
perspectives on radiation, the importance of breast sym-
metry to body image, and the importance of removing the
breast for peace of mind all help differentiate between
those patients wanting mastectomy versus breast conser-
vation.40 Surgeons should encourage patients to actively
participate in the decision-making process and try to elicit
patient’s treatment preferences. Since many patients con-
sider CPM somewhere in their decision-making process,
surgeons should make a recommendation based on their
expert opinion after weighing the evidence and reviewing
the risks and benefits of CPM with the patient.39 The sur-
geon is responsible for informing the patient about CPM’s
impact on outcomes, both physical and psychological,
engaging the patient in the decision-making process,
and ensuring that patients are making treatment decisions
that are concordant with their personal values and goals.
TABLE 1 CPM discussion guide—Information for patients regard-
ing CPM. Providers should provide this information to every patient
considering CPM for unilateral breast cancer (excluding high-risk
patients like BRCA carriers)
For most women, the estimated risk of cancer in the opposite breast
is 2–6 % over the next 10 years. This means you have a 94–
98 % chance of not getting cancer in your opposite breast over
the next 10 years or more.
CPM is not 100 % protective against cancer forming in your other
breast.
CPM will not improve your cure rate for your known cancer.
CPM will not reduce your risk of cancer returning from your
known cancer.
CPM will not reduce your need for other cancer treatments for your
known cancer (adjuvant therapy), if indicated.
The risk of surgical complications at the surgical site (such as
bleeding, infection, healing complications, and chronic pain) is
approximately twice as high when CPM is performed.
CPM results in permanent numbness of the chest wall (and nipple if
preserved).
CPM with reconstruction will result in an increased number of
operations.
Complications from CPM may delay treatment of your known
cancer, including chemotherapy and radiation that may be
recommended after surgery.
CPM may be associated with negative impact on physical,
emotional, and sexual well-being. Approximately 10 % of
women regret their decision to undergo CPM.
Breast feeding will not be possible after CPM.
Women who undergo CPM will not need mammograms or routine
breast imaging for cancer screening after surgery.
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The consensus group has compiled a template of infor-
mation that providers should include in the discussion with
every patient considering CPM for unilateral breast cancer
(excluding high-risk patients such as BRCA carriers)
(Table 1). It is highly recommended that surgeons incor-
porate this template into conversations with patients to
ensure that patients are making high-quality decisions
about their breast surgery.
Summary CPM counseling should include discussion of
CPM, risks of CPM, rates of CBC, and ensure patients are
engaged in the decision making, and making decisions that
are concordant with their treatment preferences and per-
sonal values.
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